Establishing the microbial aetiology of lower respiratory tract infections (LRTI) is essential for targeted antimicrobial therapy and effective antimicrobial stewardship. The UPLIFT study evaluated the diagnostic yield and clinical utility of a commercial multiplex PCR panel, the FilmArray Pneumonia Plus Panel (FAPP), compared with conventional culture in hospitalized patients with LRTI. The primary aims were to measure pathogen detection rates, time to result, detection of resistance markers, and the impact of test results on antimicrobial decision-making and clinical metrics.
The study prospectively enrolled 103 patients hospitalized with LRTI. For each patient, results from conventional culture (including isolate identification and antimicrobial susceptibility patterns) were recorded. Simultaneously, the FilmArray Pneumonia Plus Panel was run on appropriate respiratory specimens. The investigators documented the time taken to obtain FAPP results and the time to culture positivity. They recorded any antibiotic modifications made after receiving pathogen identification and resistance gene information from either method, and measured the time required to reach those antimicrobial decisions. Clinical outcomes captured and compared between groups included duration of antibiotic therapy and length of hospital stay.
Pathogen detection: FAPP identified at least one pathogen in 92 of 103 specimens. In contrast, conventional culture detected at least one pathogen in 36 cases (34.9%).
Antimicrobial modifications: Antimicrobial modification guided by FAPP was achieved in 83 of 103 patients (80.6%), substantially higher than modifications based on conventional culture results.
Antibiotic duration: In cases positive by FAPP, the mean duration of antibiotic therapy was 4.89 ± 1.84 days, compared with 7.2 ± 3.83 days in FAPP-negative cases. This difference reached statistical significance (P = 0.019).
Hospital length of stay: Mean duration of hospital stay for FAPP-positive cases was 5.136 ± 1.73 days versus 7.6 ± 3.36 days for FAPP-negative cases (P = 0.007).
Resistance detection: The study reports that FAPP provided better detection of resistance markers compared with conventional culture, information that contributed to antibiotic decision-making.
The results indicate a higher diagnostic yield for the multiplex PCR panel and measurable downstream effects on antibiotic use and hospitalization duration.
The UPLIFT study emphasized a markedly lower mean turnaround time (TAT) for the FilmArray Pneumonia Plus Panel compared with conventional culture. Faster availability of organism identification and resistance gene data translated into earlier actionable information for clinicians. The higher sensitivity of the multiplex PCR platform (92 positive specimens out of 103) demonstrates superior diagnostic yield over culture in this cohort. Taken together, the shortened TAT and increased detection rates underpin the greater potential of the molecular panel to influence early management decisions in hospitalized LRTI patients.
Use of FAPP in this study was associated with a substantially higher rate of antimicrobial modification (80.6% of patients) driven by panel results and resistance gene detection. Where FAPP provided a pathogen and resistance profile, clinicians were able to tailor therapy earlier. The study reports shorter mean durations of antibiotic therapy and reduced hospital stays among FAPP-positive cases compared with FAPP-negative cases, with statistically significant differences reported for both antibiotic-days (P = 0.019) and length of stay (P = 0.007). These findings suggest that multiplex PCR testing can support antimicrobial stewardship goals by enabling more rapid de-escalation or directed therapy, thereby reducing unnecessary antibiotic exposure and potentially shortening hospitalization.
In this cohort of hospitalized patients with lower respiratory tract infection, the FilmArray Pneumonia Plus Panel outperformed conventional culture in several respects: higher diagnostic sensitivity, faster turnaround time, improved detection of resistance markers, and a greater potential to guide antimicrobial modification. These advantages were associated with fewer days of antibiotic use and shorter hospital stays in FAPP-positive cases compared with FAPP-negative cases. The authors conclude that implementing multiplex PCR testing with FAPP can enhance pathogen detection and support optimized antimicrobial management in hospitalized LRTI patients.